Navigation Links
Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer
Date:5/14/2013

FREMONT, Calif., May 14, 2013 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with the appointment of Nandan Oza as the company's Chief Operations Officer. In this position, Mr. Oza will guide the company's efforts in manufacturing, quality and engineering – vital activities to enable the company to accelerate the development of its innovative multi-product portfolio.

"I am pleased to welcome Nandan as our COO," said Vikram Lamba, Chief Executive Officer, Zosano Pharma. "His operational and manufacturing experience and expertise – as well as his leadership experience – will be critical in preparing Zosano for our next stage of commercial-scale manufacturing as we drive our clinical programs towards the marketplace."

Prior to joining Zosano Pharma, Mr. Oza served as Vice President, Chemistry, Manufacturing and Controls at Talon Therapeutics. He previously held the position of Vice President, Manufacturing and Supply Chain Operations at Jazz Pharmaceuticals and at Connetics Corporation (now a part of GSK). Mr. Oza also held positions of increasing responsibility at ALZA Pharmaceuticals (now part of Johnson and Johnson) in Product Development, Quality and Technical and Manufacturing Operations, progressing to his role as Executive Director, Bay Area Operations. Mr. Oza earned a Bachelor's degree (with honors) in Mechanical Engineering from the University of Houston, pursued graduate studies in Engineering from the University of California, Davis and earned an MBA from National University, San Diego, CA.

"This is an exciting time to join the Zosano Pharma team," said Mr. Oza. "The company is well positioned to move forward in commercial scale manufacturing with its ZP Patch Technology and advancing development-stage product pipeline."

About Zosano Pharma
Zosano Pharma, Inc. is a private biopharmaceutical company and a pioneer in the field of drug delivery systems. Zosano is developing products using ZP Patch Technology, a novel transdermal delivery technology based on microprojections that provide rapid and efficient systemic delivery in a convenient, needle–free, and pain–free system. Zosano is a fully integrated development company with a recently launched cGMP manufacturing capability. The company is developing products with significant commercial potential both independently and in collaboration with strategic partners. Learn more at http://www.zosanopharma.com.


'/>"/>
SOURCE Zosano Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
2. Zosano Pharma, Inc. Announces Key Strategic Hire
3. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
4. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
5. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
6. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
7. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
8. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
11. Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... YORK , April 19, 2017 Global ... drainage devices are tubes used to remove excess liquid ... blood, serum, pus, urine, bile or lymph. Surgical drains ... of surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, ... is prophylactic post-surgery to prevent accumulation of fluid e.g. ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
(Date:4/18/2017)... 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), a ... Uro/Gyn and Gynecology markets with innovative and proprietary products, ... March 31, 2017 after the market close on Tuesday, ... host a conference call and webcast to discuss its ... 2017 at 4:30 p.m. Eastern Time (3:30 p.m. Central ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of ... pain with a reputable physician in their area, announces the launch of a new ... for patients who are looking for reputable physicians to help them with back or ...
(Date:4/25/2017)... NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed ... treatment of acute or chronic problems, I focus on preventative care with all my patients ... you have any questions, always feel free to contact my office and my trained staff ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol ... is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex ... in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College ... nursing professionals advance their careers. Beginning in the fall of 2017, Emmanuel’s program will ... in as few as 16 months and for as little as $14,528. These changes ...
Breaking Medicine News(10 mins):